Author(s):
Simran Goel, Sristi Anupam, Dinesh Kumar Mehta, Rina Das
Email(s):
rinammu@gmail.com
DOI:
10.52711/0974-360X.2025.00143 
Address:
Simran Goel, Sristi Anupam, Dinesh Kumar Mehta, Rina Das*
M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana, Ambala, HR, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2025
ABSTRACT:
Objective: To assess the relationship between serum liver enzyme activity and other biochemical parameters of liver function test (LFT) among hypertensive patients with Type II diabetes mellitus (T2DM). Research Design and Method: The research enrolled 276 participants in total. All of the patients were split into three groups based on their illness states: diabetes (42%), hypertension (HTN) (14.75%) and both (40.25%). Monitoring of blood pressure (BP), blood sugar, and laboratory testing for SGOT, SGPT, ALP, bilirubin, and albumin were all included in the analysis. Result: High levels of Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), and albumin were more common in females than in men in each group, although raised levels of Alkaline phosphatase (ALP) and bilirubin were more common in males. Diabetic patients with mixed diets had greater instances of elevated LFT values in comparison with vegetarians. A positive correlation is also observed from the data that as the duration of the disease increases LFT values for each category also increases. Conclusion: These findings imply that people with T2DM and HTN have liver enzyme levels that are noticeably higher. The risk of liver damage may be increased in part by T2DM and HTN.
Cite this article:
Simran Goel, Sristi Anupam, Dinesh Kumar Mehta, Rina Das. Association between Serum Liver Enzymes among Hypertensive Type II Diabetes Mellitus patients: A Cross-sectional Study. Research Journal Pharmacy and Technology. 2025;18(3):1001-5. doi: 10.52711/0974-360X.2025.00143
Cite(Electronic):
Simran Goel, Sristi Anupam, Dinesh Kumar Mehta, Rina Das. Association between Serum Liver Enzymes among Hypertensive Type II Diabetes Mellitus patients: A Cross-sectional Study. Research Journal Pharmacy and Technology. 2025;18(3):1001-5. doi: 10.52711/0974-360X.2025.00143 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-3-4
REFERENCES:
1. Roden, M.; Shulman, G.I. The integrative biology of type 2 diabetes. Nature. 2019; 576; 51–60.
2. Gaede P et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003,
3. Leffert H. L et al. Hormonal control of rat liver regeneration. Gastroenterology. 1979; 76:1470-82.
4. Philip R et al. Evalation of relationship between markers of liver function and the onset of type 2 diabetes. Nitte Univ J Health Sci. 2014; 4(2):90
5. Jeanrenaud B, Insulin and obesity. Diabetolcgia 1979; 17:133- 38.
6. Creutzfeldt W, Frerichs H, and Sickinger K, Liver disease and diabetes mellitus. In Progress in Liver Disease, Vol. 3. Popper, H., and Schaffner, F., Eds. New York, Grune and S Tatton, 1970:371- 407.
7. Reaven E. P, Peterson D. T and Reaven G. M, The effect of experimental diabetes mellitus and insulin replacement on hepatic ultrastructure and protein synthesis. J. CLin. Invest. 1973; 52: 248-62
8. Lee D-H et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the coronary artery risk development in young adults (CARDIA) study. Clin Chem. 2003; 49: 1358–66.
9. Bonnet F et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017; 35: 493–500.
10. Stumvoll M et al. Type 2 diabetes: Principles of pathogenesis and therapy. Lancet. 2005; 365: 1333–136.
11. Cerf M.E, Beta cell dysfunction and insulin resistance. Front. Endocrinol. (Lausanne). 2013; 4: 37.
12. Suraj V. Bondre, Rushikesh S. Chavan, Indrayani D. Raut, Shrinivas K. Mohite, Chandrakant S. Magdum. An Overview of Survey on Antihypertensive Drugs. Asian J. Pharm. Res. 2020; 10(3): 160-162.
13. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012; 380:601–610. doi: 10.1016/S0140-6736(12): 60987-8.
14. Perreault L et al. Diabetes Prevention Program Research Group. Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabet Med. 2017; 34:1747–1755. doi: 10.1111/dme.13453.
15. C Sasi Sulochana, Sharmila Jansi Rani. Quasi Experimental Study to assess the relationship between Lifestyle and Blood Pressure among Prehypertensive employees in a workplace hypertension prevention program at Kanyakumari District, Tamil Nadu. Asian J. Nursing Education and Research. 2019; 9(3): 323-326.
16. Mohd. Yaqub Khan, Poonam Gupta, Bipin Bihari, Vikas Kumar Verma. A Review on Diabetes and Its Management. Asian J. Pharm. Res. 2013; 3(1): 27-32.
17. Ban N etal. Activating transcription factor-2 is a positive regulator in CaM kinase IV-induced human insulin gene expression. Diabetes. 2000; Jul 1; 49(7): 1142-8.
18. Izzo R etal. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009; May 1; 32(5): 845-50.
19. Ankita Singh et al. Serum Biomarkers for Noninvasive Diagnosis of Liver Diseases: How laudable are these tools? Current Chemical Biology. 2021; 15(2): 128-138.
20. Kaushal K Sah et al. Prescription pattern of type-2 Diabetes management in the geriatric patients, Journal of Young Pharmacists. 2022; 14 (4): 416-419.
21. National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560–2571.
22. Chobanian AV. National heart, lung, and blood institute; national high blood pressure education program coordinating committee. seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003; 42: 1206–52.
23. Kalaivanan S, Sarumathy S, Anisha Ebens J, Naresh Kumar K, Roobena Parveen A, Nasreen Ashraf M. Clinical Assessment and Comparison of Lipid Profiles among Coronary Artery Disease and type 2 Diabetes Mellitus Patients receiving Statin Therapy. Research J. Pharm. and Tech. 2017; 10(1): 18-20.